The use of free combination of inhaled glucocorticosteroid and long-acting β2-agonist in patients with bronchial asthma: clinical examples
- Authors: Sebekina O.V1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 3 (2017)
- Pages: 109-114
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94890
- ID: 94890
Cite item
Full Text
Abstract
The goal of asthma treatment is to achieve good control of symptoms and maintain normal activity level of the patient, minimizing the risk of future exacerbations and side effects of treatment. In accordance with modern guidelines, starting with stage 3 (moderate bronchial asthma patients) is the preferred therapy combination drugs with a combination of low-dose inhaled corticosteroids and long-acting b2-agonists.A meta-analysis of several studies demonstrated that the use of free combination of budesonide and formoterol significantly: improve lung function; reduce the need for short-acting b2-agonists; to improve the quality of life; reduce the number of exacerbations requiring hospitalization, call the ambulance, or the use of systemic corticosteroids. The use of free combination of budesonide and formoterol was accompanied by a high level of compliance. The article describes the clinical cases of the use of free combination of budesonide and formoterol in patients with asthma.
Full Text
##article.viewOnOriginalSite##About the authors
O. V Sebekina
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: sebekina74@bk.ru
канд. мед. наук, ассистент каф. клин. Аллергологии ФГБОУ ДПО РМАНПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
References
- Global Strategy for Asthma Management and Prevention. Global Initiative for Asthm (GINA). Updated 2015. www.ginasthma.org
- Nathan R.A, Nayak A.S, Graft D.F et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma. Immunol 2001; 86 (2): 203-10.
- Greening A.P, Ind P.W, Northfield M, Shaw G. Added salmeterol versus higher - dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344 (8917): 219-24.
- Woolcock A, Lundback B, Ringdal N, Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153 (5): 1481-8.
- Pauwels R.A, Lofdahl C.G, Postma D.S et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337 (20): 1405-11.
- Kips J.C, O′Connor B.J, Inman M.D et al. A long - term study of the antiinflammatory effect of low - dose budesonide plus formoterol versus high - dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161 (3 Pt 1): 996-1001.
- Barnes P.J. Scientific rationale for inhaled combination therapy with long - acting beta2 - agonists and corticosteroids. Eur Respir J 2002; 19 (1): 182-91.
- Mak J.C, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest 1995; 96 (1): 99-106.
- Braido F, Baiardini I, Compalati E et al. Towards the Grade of Recommendations, Assessment, Development and Evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. Curr Opin Allergy Clin Immunol 2011; 11(4): 361-74.
- O'Byrne P.M, Bisgaard H, Godard P.Pet al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (2): 129-36.
- Kuna P et al. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher mainte_nance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.
- Rabe K.F, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double blind study. Lancet2006; 368: 744-53.
- Vogelmeier C, D'Urzo A, Pauwels R† et al.Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-28.
- Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (9): 1403-18.
- Rabe K.F, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler formaintenance and relief in mild to moderate asthma: a randomized, double blind trial. Chest 2006; 129 (2): 246-56.
- Sears M.R, Ottosson A, Radner F, Suissa S. Long - acting b - agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33: 21-32.
- Чучалин А.Г., Белевский A.C., Смоленов И.В. и д р. Качество жизни больных бронхиальной астмой в России: результаты многоцентрового популяционного исследования. Пульмонология. 2003; 5: 88-96.
- Meyer T et al. Deposition sverteilung von Steroiden bei Patientenmit Asthma bronchiale nach Inhalation von Formoterol. Pneumologie 2004; 58: 16.
- Белевский А.С., Цветкова О.А. Форадил Комби: эффективность, безопасность и комплайнс у пациентов с бронхиальной астмой. Результаты всероссийской программы ФРИСТАЙЛ 2. Атмосфера. Пульмонология и аллергология. 2013;(3): 29-34.
- Чучалин А.Г. и др. Атмосфера. Пульмонология и аллергология. 2009; 4: 26.
- Чучалин А.Г., Визель А.А. и др. Результаты российского наблюдательного исследования ФРИСТАЙЛ (Форадил Комби: эффективность, безопасность и комплайнс у пациентов с бронхиальной астмой). Атмосфера. Пульмонология и аллергология. 2011; 2: 21-6.
- Meyer T et al. Depositionsverteilung von Steroiden bei Patienten mit Asthma bronchiale nach Inhalation von Formoterol. Pneumologie 2004; 58: 16.
Supplementary files
